BR9912156A - Composto, composição farmacêutica, uso de um composto, e, processos para o tratamento de uma infeção por retrovìrus em um ser humano e para a preparação de um composto. - Google Patents

Composto, composição farmacêutica, uso de um composto, e, processos para o tratamento de uma infeção por retrovìrus em um ser humano e para a preparação de um composto.

Info

Publication number
BR9912156A
BR9912156A BR9912156-5A BR9912156A BR9912156A BR 9912156 A BR9912156 A BR 9912156A BR 9912156 A BR9912156 A BR 9912156A BR 9912156 A BR9912156 A BR 9912156A
Authority
BR
Brazil
Prior art keywords
compound
processes
preparation
treatment
human
Prior art date
Application number
BR9912156-5A
Other languages
English (en)
Other versions
BRPI9912156B1 (pt
BRPI9912156B8 (pt
Inventor
Ian Gordon Armitage
Andre David Searle
Hardev Singh
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9912156A publication Critical patent/BR9912156A/pt
Publication of BRPI9912156B1 publication Critical patent/BRPI9912156B1/pt
Publication of BRPI9912156B8 publication Critical patent/BRPI9912156B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

''COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSOS PARA O TRATAMENTO DE UMA INFEçãO POR RETROVìRUS EM UM SER HUMANO E PARA A PREPARAçãO DE UM COMPOSTO'' A invenção diz respeito a (3S)tetraidro-3-furanil-(1S,2R)-3-[[(4-aminofenil)sulfonil[(isobutil)amino ]-1-benzil-2-(fosfonoóxi)propilcarbamato de cálcio, a processos para a sua preparação e a seu uso no tratamento de doenças causadas por retrovírus.
BRPI9912156A 1998-07-18 1999-07-15 processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina BRPI9912156B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound
PCT/EP1999/004991 WO2000004033A1 (en) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Publications (3)

Publication Number Publication Date
BR9912156A true BR9912156A (pt) 2001-04-10
BRPI9912156B1 BRPI9912156B1 (pt) 2016-07-26
BRPI9912156B8 BRPI9912156B8 (pt) 2021-05-25

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912156A BRPI9912156B8 (pt) 1998-07-18 1999-07-15 processo para a preparação do sal de (3s)-tetraidro-3-furanil-(1s,2r)-3-[[(4-aminofenil)-sulfonil] (isobutil)amino]-1-benzil-2-fosfonóxi)propilcarbamato de cálcio em uma forma cristalina

Country Status (48)

Country Link
US (3) US6514953B1 (pt)
EP (2) EP1240903A3 (pt)
JP (1) JP3437553B2 (pt)
KR (1) KR100694721B1 (pt)
CN (1) CN1188422C (pt)
AP (1) AP2001002039A0 (pt)
AR (1) AR019388A1 (pt)
AT (1) ATE229964T1 (pt)
AU (1) AU766056B2 (pt)
BG (1) BG105253A (pt)
BR (1) BRPI9912156B8 (pt)
CA (1) CA2337857C (pt)
CO (1) CO5090836A1 (pt)
CZ (1) CZ300447B6 (pt)
DE (1) DE69904600T2 (pt)
DK (1) DK1098898T3 (pt)
DZ (1) DZ2845A1 (pt)
EA (1) EA003191B1 (pt)
EE (1) EE200100038A (pt)
ES (1) ES2189450T3 (pt)
GB (1) GB9815567D0 (pt)
GC (1) GC0000105A (pt)
GE (1) GEP20033030B (pt)
GT (1) GT199900111A (pt)
HK (1) HK1034261A1 (pt)
HR (1) HRP20010046A2 (pt)
HU (1) HU229700B1 (pt)
ID (1) ID28070A (pt)
IL (1) IL140824A (pt)
IS (1) IS5808A (pt)
JO (1) JO2114B1 (pt)
MA (1) MA26660A1 (pt)
MY (1) MY122323A (pt)
NO (1) NO329676B1 (pt)
NZ (1) NZ509291A (pt)
OA (1) OA11706A (pt)
PA (1) PA8477801A1 (pt)
PE (1) PE20000869A1 (pt)
PL (1) PL195736B1 (pt)
PT (1) PT1098898E (pt)
SK (1) SK285311B6 (pt)
SV (1) SV1999000096A (pt)
TN (1) TNSN99145A1 (pt)
TR (1) TR200100111T2 (pt)
TW (1) TWI245770B (pt)
WO (1) WO2000004033A1 (pt)
YU (1) YU3401A (pt)
ZA (1) ZA200100417B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
RU2247123C2 (ru) * 1999-10-06 2005-02-27 Тиботек Фармасьютикалз Лтд. Гексагидрофуро [2,3-b] фуран-3-ил-n-{3-[(1,3-бензодиоксол-5- илсульфонил)(изобутил)амино]-1-бензил -2-гидроксипропил}карбамат, фармацевтическая композиция на их основе, способы ингибирования и способ лечения
CZ302015B6 (cs) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
ATE367394T1 (de) * 2002-04-26 2007-08-15 Gilead Sciences Inc Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
JP4859460B2 (ja) * 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
AU2004233897A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
MXPA05011297A (es) 2003-04-25 2006-05-25 Gilead Sciences Inc Analogos antivirales de fosfonato.
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
WO2005030194A1 (en) * 2003-09-30 2005-04-07 Tibotec Pharmaceuticals Ltd. Hcv inhibitiing sulfonamides
EP1680512A1 (en) 2003-10-24 2006-07-19 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
ATE424400T1 (de) 2003-12-22 2009-03-15 Gilead Sciences Inc 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv- antiviraler wirkung
PT1828167E (pt) 2004-06-04 2014-10-08 Debiopharm Int Sa Derivados de acrilamida como agentes antibióticos
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
ATE457187T1 (de) 2004-11-26 2010-02-15 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
KR20080075027A (ko) * 2005-12-05 2008-08-13 아피늄 파마슈티컬스, 인크. Ｆａｂｉ 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
EP3255045A1 (en) * 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
JP5448854B2 (ja) 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
DK3263100T3 (da) 2009-04-03 2020-05-11 Ocera Therapeutics Inc L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
EP2432788A1 (en) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
CA2764587C (en) 2009-06-08 2018-04-24 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
EP2448949A1 (en) * 2009-06-30 2012-05-09 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
EP2477996A1 (en) * 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
US20110165202A1 (en) * 2010-01-07 2011-07-07 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
SG10201707183TA (en) 2010-01-27 2017-10-30 Viiv Healthcare Co Antiviral therapy
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) * 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
EP2614055A2 (en) 2010-09-10 2013-07-17 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
EA028395B1 (ru) 2010-10-06 2017-11-30 Осера Терапьютикс, Инк. Способы получения фенилацетата l-орнитина
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
TR201909016T4 (tr) 2012-06-19 2019-07-22 Debiopharm Int Sa (E)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamidin ön ilaç türevleri.
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
WO2018208677A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
JP2001527062A (ja) * 1997-12-24 2001-12-25 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼインヒビターのプロドラッグ
WO1999033792A2 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
US6147095A (en) * 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
CA2391643C (en) * 1999-11-24 2010-01-12 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Also Published As

Publication number Publication date
GC0000105A (en) 2005-06-29
TNSN99145A1 (fr) 2005-11-10
CA2337857C (en) 2011-01-25
US6514953B1 (en) 2003-02-04
ATE229964T1 (de) 2003-01-15
GT199900111A (es) 2001-01-05
CO5090836A1 (es) 2001-10-30
IL140824A (en) 2004-09-27
CZ300447B6 (cs) 2009-05-20
NO20010282L (no) 2001-03-07
PL195736B1 (pl) 2007-10-31
DZ2845A1 (fr) 2003-12-01
CZ2001219A3 (cs) 2001-07-11
KR100694721B1 (ko) 2007-03-15
WO2000004033A1 (en) 2000-01-27
IS5808A (is) 2001-01-12
BG105253A (en) 2001-12-29
ZA200100417B (en) 2002-02-27
GEP20033030B (en) 2003-07-25
HUP0103432A2 (hu) 2002-04-29
EP1240903A3 (en) 2003-02-12
DE69904600T2 (de) 2003-11-13
EP1240903A2 (en) 2002-09-18
SK285311B6 (sk) 2006-10-05
BRPI9912156B1 (pt) 2016-07-26
SK762001A3 (en) 2001-10-08
MY122323A (en) 2006-04-29
US20030096795A1 (en) 2003-05-22
TR200100111T2 (tr) 2002-02-21
SV1999000096A (es) 2000-07-06
HRP20010046A2 (en) 2002-02-28
EP1098898B1 (en) 2002-12-18
PE20000869A1 (es) 2000-09-08
JP3437553B2 (ja) 2003-08-18
NZ509291A (en) 2003-05-30
HU229700B1 (en) 2014-05-28
GB9815567D0 (en) 1998-09-16
TWI245770B (en) 2005-12-21
DK1098898T3 (da) 2003-04-07
AU766056B2 (en) 2003-10-09
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
JP2003521447A (ja) 2003-07-15
AR019388A1 (es) 2002-02-13
PT1098898E (pt) 2003-04-30
AP2001002039A0 (en) 2001-03-31
PA8477801A1 (es) 2000-05-24
JO2114B1 (en) 2000-05-21
EA200100053A1 (ru) 2001-08-27
ES2189450T3 (es) 2003-07-01
YU3401A (sh) 2005-06-10
CA2337857A1 (en) 2000-01-27
CN1188422C (zh) 2005-02-09
EE200100038A (et) 2002-06-17
NO20010282D0 (no) 2001-01-17
EP1098898A1 (en) 2001-05-16
DE69904600D1 (de) 2003-01-30
PL345620A1 (en) 2002-01-02
EA003191B1 (ru) 2003-02-27
ID28070A (id) 2001-05-03
HUP0103432A3 (en) 2003-01-28
BRPI9912156B8 (pt) 2021-05-25
IL140824A0 (en) 2002-02-10
NO329676B1 (no) 2010-11-29
CN1324363A (zh) 2001-11-28
AU5037999A (en) 2000-02-07
OA11706A (en) 2005-01-13
MA26660A1 (fr) 2004-12-20
HK1034261A1 (en) 2001-10-19

Similar Documents

Publication Publication Date Title
BR9912156A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para o tratamento de uma infeção por retrovìrus em um ser humano e para a preparação de um composto.
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
MX172600B (es) , "procedimiento para la produccion de una proteina biologicamente activa
BR9808348A (pt) Alimento medicinal para diabéticos
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
MY125821A (en) Pharmaceutical composition of topiramate
MXPA02006679A (es) Composicion farmaceutica.
BR0113590A (pt) 7-oxo-piridopirimidinas
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK440888A (da) Hjaelpestoffer som resorptionsfremmende stoffer af peptider og proteiner ved paafoering paa slimhinder samt anvendelse deraf g praepparat indeholdende hjaelpestofferne
BRPI0410195A (pt) compostos quìmicos
BR9911005A (pt) Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias
HUP0402092A2 (hu) 2-[5-(4-Fluorfenil)-3-piridilmetilaminometil]-kromán vegyületek és fiziológiásan elfogadható sói alkalmazása gyógyszerkészítmények előállítására
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
DK0972521T3 (da) Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
BR0104005A (pt) Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
BR9807288A (pt) Utilização dos compostos ß3-agonistas, composição farmacêutica para a profilaxia e/ou para o tratameos.
BR9712805A (pt) Processo para a preparação de compostos farmecêuticos
DE60114844D1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen
BR0013921A (pt) Composições farmacêuticas para tratamento de psorìase
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 11, 13 E 25 COMBINADOS COM O ART. 37 DA LEI 9.279/1996 ( LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/07/2019

B15V Prolongation of time limit allowed